Point: Postprandial Glucose Levels Are a Clinically Important Treatment Target
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The results of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial have been recently reported (1–2). Nateglinide, a member of the meglitinide class, which has been shown to lower postprandial hyperglycemia by increasing the first phase of insulin secretion, was not effective in decreasing both the new cases of diabetes and the new cardiovascular events in a population at high risk (1). Valsartan, an angiotensin (AT-1) blocker, was ineffective on cardiovascular events but significantly—even marginally—reduced the onset of new diabetes (2). The negative results of nateglinide immediately raised the concern about the possibility that postprandial hyperglycemia could be considered an independent risk factor for cardiovascular disease (CVD) and whether its treatment may give any advantage in the management of diabetes (3). Diabetologists have long debated whether the lack of insulin action (insulin resistance) or impaired insulin secretion represents the primary pathological mechanism underlying type 2 diabetes. Recent analyses confirm that impaired pancreatic β-cell glucose sensitivity and whole-body insulin sensitivity are strong predictors of a progression to hyperglycemia (4). Conversely, numerous studies have shown that acute insulin secretion defects represent a powerful early predictor of diabetes progression. During the progression from normal glucose tolerance to increasingly severe type 2 diabetes, first-phase insulin secretion (FPIS) is an early casualty. Prior to the diagnosis of diabetes, insulin response to mealtime glucose becomes delayed and blunted; eventually, it is lost (5). In a landmark study, Polonsky et al. (5) showed that FPIS responses were more sluggish and less dramatic in diabetic individuals. In another analysis, a marked and increasing loss of the early-phase β-cell secretory response to a meal challenge correlated with increasing postprandial hyperglycemia in a group of individuals recently diagnosed with diabetes (6). Together these data indicate that declining FPIS and postprandial hyperglycemia are key …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., Laakso, M., & for The STOP-NIDDM Trial Research Group (2003) · JAMA · doi:10.1001/jama.290.4.486 · Cited by 1,624
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
Three-year efficacy of complex insulin regimens in type 2 diabetes
Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., & Paul, S. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905479 · Cited by 667
Effect of valsartan on the incidence of diabetes and cardiovascular events
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001121 · Cited by 660 · cited 14×
“This concept is strengthened during the study by the need to change the primary outcome, including a third coprimary core cardiovascular outcome, previously designated as a secondary outcome (1).”
BackgroundInfluentialHanefeld, M. (2004) · European Heart Journal · doi:10.1016/s0195-668x(03)00468-8 · Cited by 641
Cavalot, F., Petrelli, A., Traversa, M., Bonomo, K., Fiora, E., Conti, M., Anfossi, G., Costa, G., & Trovati, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1005 · Cited by 569
Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus.
Polonsky, K. S., Given, B. D., Hirsch, L. J., Tillil, H., Shapiro, E. T., Beebe, C., Frank, B. H., Galloway, J. A., & Van Cauter, E. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805123181903 · Cited by 567
Effect of nateglinide on the incidence of diabetes and cardiovascular events
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001122 · Cited by 477
Postprandial Glucose Regulation and Diabetic Complications
Ceriello, A. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.19.2090 · Cited by 362 · cited 2×
“pothesis (11), including the recent data of”
BackgroundSelf-citationRaz, I., Wilson, P. W. F., Strojek, K., Kowalska, I., Bozikov, V., Gitt, A. K., Jermendy, G., Campaigne, B. N., Kerr, L., Milicevic, Z., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1671 · Cited by 351 · cited 3×
“However, the Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (HEART2D) study (18) last year and the NAVIGATOR (1) study now, have failed to confirm this finding.”
BackgroundMethod
Cited by
Mechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890
“Although glucose variability is still considered by certain investigators to play a role in susceptibility and progression of diabetic complications (80, 401), it is possible that hypoglycemia per se, often seen in diabetic subjects with increased glucose excursions, plays a key role in explaining some of the deleteri…”
BackgroundEndothelial dysfunction — A major mediator of diabetic vascular disease
Sena, C. M., Pereira, A. M., & Seiça, R. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.08.006 · Cited by 797
Kaur, R., Kaur, M., & Singh, J. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0763-3 · Cited by 736
Augustin, L. S. A., Kendall, C. W. C., Jenkins, D. J. A., Willett, W. C., Astrup, A., Barclay, A. W., Björck, I., Brand-Miller, J. C., Brighenti, F., Buyken, A. E., et al. (2015) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2015.05.005 · Cited by 707
Self-citationCavalot, F., Pagliarino, A., Valle, M., Di Martino, L., Bonomo, K., Massucco, P., Anfossi, G., & Trovati, M. (2011) · Diabetes Care · doi:10.2337/dc10-2414 · Cited by 322
“The mechanisms involved in the association between postprandial blood glucose and cardiovascular events have previously been described (4,20).”
Background
Metadata
- Authors
- Ceriello, A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-08-01
- Volume
- 33
- Issue
- 8
- Pages
- 1905-1907
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2076205364
- Cited by
- 49
- References
- 13
- FWCI
- 2.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Point: Postprandial Glucose Levels Are a Clinically Important Treatment Target. https://app.cochat.ai/papers/10.2337/dc10-0634
- The paper
- Ceriello, A. (2010). Point: Postprandial Glucose Levels Are a Clinically Important Treatment Target. Diabetes Care. https://doi.org/10.2337/dc10-0634
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.